Street Calls of the Week
TEL AVIV - SciSparc Ltd. (NASDAQ:SPRC), a small-cap pharmaceutical company with a market capitalization of $6.46 million, announced today it has closed a transaction giving it a controlling interest in Neurothera Labs Inc. (TSXV:NTLX), a company traded on the TSX Venture Exchange in Canada. According to InvestingPro analysis, SciSparc is currently trading near its Fair Value, with strong liquidity metrics showing a current ratio of 5.36.
Under the agreement, SciSparc acquired approximately 75% of Neurothera, which could increase to 84% if certain conditions are met. The deal involved SciSparc transferring its clinical-stage pharmaceutical portfolio and its 51% stake in SciSparc Nutraceuticals to Neurothera.
The transaction valued Neurothera at approximately US$3.3 million and the transferred assets at US$11.6 million. SciSparc received 63,300,000 common shares, 4,000,000 share purchase warrants, and up to 48,000,000 contingent rights of Neurothera.
As part of the deal, SciSparc committed CAD 1,000,000 (approximately US$716,000) to Neurothera through an unsecured convertible note maturing in October 2027.
Neurothera, formerly known as Miza III Ventures Inc., changed its name and trading symbol from MIZA.P to NTLX effective October 22. Trading of Neurothera shares, which was halted since July 8, 2024, is expected to resume today.
The transaction securities are subject to an escrow agreement, with 10% to be released upon the final bulletin of the TSXV and an additional 15% every six months thereafter.
SciSparc is a clinical-stage pharmaceutical company focused on developing cannabinoid-based treatments for disorders of the central nervous system. While currently not profitable, InvestingPro analysis indicates analysts expect the company to turn profitable this year. The information in this article is based on a company press release statement. Subscribers to InvestingPro can access 9 additional exclusive insights about SciSparc’s financial health and growth prospects.
In other recent news, SciSparc Ltd. announced a definitive agreement to acquire a controlling interest in Miza III Ventures Inc., a Canadian-listed company. Under the terms of the deal, SciSparc will transfer its advanced clinical-stage pharmaceutical portfolio and a 51% equity stake in SciSparc Nutraceuticals to Miza, valued at approximately $11.6 million. In exchange, SciSparc will receive 63,300,000 common shares of Miza and up to 48,000,000 contingent rights based on pre-determined milestones. Additionally, SciSparc launched an initiative to advance 3D protein modeling using quantum computing technology, aiming to enhance drug discovery through improved accuracy in predicting protein structures. This initiative was approved by the company’s board of directors on September 16, 2025. In other developments, SciSparc and AutoMax Motors have mutually agreed to terminate their previously planned merger, including the repayment terms for two outstanding loans provided to AutoMax. These recent developments reflect SciSparc’s strategic focus on expanding its pharmaceutical interests and technological capabilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.